BAM
ADAP

Blueshift Asset Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Blueshift Asset Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11,933
Closed -$62K – 808
2021
Q3 		$62K Buy
+11,933
New +$53.5K ﹤0.01% 970

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Blueshift Asset Management's ADAP Position: Q4 2021 in Review

Blueshift Asset Management sold out of Adaptimmune Therapeutics (ADAP) in Q4 2021, closing a stake of 11,933 shares — an estimated $62K sold.

Blueshift Asset Management first reported a position in ADAP in Q3 2021 and held it in 1 quarter. The position peaked at $62K in Q3 2021. 85 funds tracked by Wall St. Rank hold ADAP as of Q4 2021.

  • Blueshift Asset Management reported no remaining Adaptimmune Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Blueshift Asset Management sold 11,933 Adaptimmune Therapeutics shares in Q4 2021, an estimated $62K.
  • Blueshift Asset Management first reported a position in Adaptimmune Therapeutics in Q3 2021 and held it in 1 quarter.
  • Blueshift Asset Management's Adaptimmune Therapeutics position peaked at $62K in Q3 2021.
  • 85 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2021.

Based on Blueshift Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.